Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

about

Breast liposarcoma with solitary metastasis to the pleura: A case report.

P2860

Q33885787-C4BDB4E4-9220-4716-820C-952CD33C5E5E

P2860

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

Item

http://www.wikidata.org/entity/Q28078116

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@ast

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@en

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@nl

type

Item

label

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@ast

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@en

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@nl

prefLabel

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@ast

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@en

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@nl

P1476

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

@en

P2093

Jonathan Noujaim

http://www.w3.org/2001/XMLSchema#string

Khin Thway

http://www.w3.org/2001/XMLSchema#string

Salma Alam

http://www.w3.org/2001/XMLSchema#string

P2860

Eribulin in Cancer Treatment

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Eribulin mesylate in patients with refractory cancers: a Phase I study.

P304

125-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4667874

http://www.w3.org/2001/XMLSchema#string

P356

10.4103/0971-5851.190359

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robin L Jones

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27688604

http://www.w3.org/2001/XMLSchema#string

P932

5027783

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

about

P2860

P2860

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P698

P932

P3181

P356

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P698

P932